SeQuent Eyes Ebitda Growth Of 200 Basis Points Or More In Fourth Quarter
A practitioner at the GuoGuo TCM Neurology and Acupuncture Animal Health Center in Shanghai. (Photographer: Qilai Shen/Bloomberg)

SeQuent Eyes Ebitda Growth Of 200 Basis Points Or More In Fourth Quarter

Bookmark
Animal healthcare company SeQuent Scientific Ltd. said it expects its fourth quarter Ebitda margin to see a growth of at least 200 basis points, with a run rate edging over Rs 300 crore.“We should ...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.